Key Updates in CLL From ASH 2023

Forgot your password?

Select specialty

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

By Seema Bhat 3 Videos

March 11, 2024

Feat. C. Harrison

West Oncology Conference

Sat, Feb 8, 2025

Danielle Brander

Louisville Hematology Highlights

Integrity CE

M. Cortese, D. Wallace, A. Niu

SOHO Brazil 2024

SOHO Brazil 2024

Nicole Lamanna

XV Eurasian Hematology-Oncology Congress - EHOC 2024

City of Hope

Massachusetts General Hospital Cancer Center

Indy Hematology Review

Nicole Lamanna

SOHO Brazil 2024

2024 ASCO® Annual Meeting Insights Hub

K. Rogers, J. Woyach

UChicago Medicine

City of Hope

Farrukh Awan

Ruemu Birhiray

Total Health

Matthew McKinney

Login

Login

Join VuMedi

Key Updates in CLL From ASH 2023

FLAIR Study & Treatment Personalization in CLL

MRD-Negative Status & PFS Improvement with Ibrutinib Plus Venetoclax

Evaluating CLL Outcomes Based on IgHV & FISH Status

Long-Term Outcomes with BTK Inhibitors in High-Risk CLL

ELEVATE-TN Study: Acalabrutinib Combination Therapy Advantage

ALPINE Study: Zanubrutinib vs. Ibrutinib in Relapsed/Refractory CLL

Safety and Efficacy of Pirtobrutinib in CLL

Importance of Early Management of Patients with Myelofibrosis (MF)

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Related Videos

West Oncology Conference

Choosing BTKi or BCL2i or Combination Therapy for 1L CLL

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Clinical Practice Updates in CLL/SLL

1L Therapy in CLL: What Are the Best Options?

3L in CLL: The Best Options in a Patient Double-Refractory to Covale…

Sequencing Therapies in CLL: The Importance of First-Line Treatment …

Debates in CLL: Continuous or Finite Duration Therapy

CLL Treatment Sequencing: The Importance of First Choice

Practice-Changing Updates in Indolent B-Cell Lymphomas

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Pirtobrutinib in CLL: Current and Potential Utility in the Treatment…

Single vs. Multiple Agents in 2L Therapy for CLL

Experts Discuss Highlights and Key Takeaways in CLL From ASCO® and E…

The Next Frontier of Targeted Therapy in Lymphoma

Venetoclax vs. BTKis in CLL Treatment

Guideline-Based Treatment Approaches in CLL

Impact of Ibrutinib Dose Modifications in CLL

Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL…

Managing Cardiotoxicities in TKI Therapy for CLL: Atrial Fibrillatio…

Guidelines for Dose Reduction of Ibrutinib in CLL